Disodium Succinoyl Farnesylcysteine for Skin Rejuvenation - Quick Reference Sheet
evipedia.ai
← Back

Disodium Succinoyl Farnesylcysteine for Skin Rejuvenation

Created on 08/11/2026 – Quick Reference based on Evidence Review created using AI4L / Opus 5 – Audit

A synthetic topical ingredient that imitates the fatty anchor signal-carrying proteins use in cell membranes, quieting inflammatory messaging that follows sun, pollution, and irritation. Human results show visible improvement in crow's feet, texture, radiance, hydration, and facial redness, with good tolerance. The manufacturer designed, funded, and published essentially every result; no independent group has repeated the work. (Full Review)

Protocol

Studied concentration and frequency
1% gel, twice daily
The only vehicle-controlled exposure, over 12 weeks; the rosacea pilot used 3% for 4 weeks.
Best time of day
Morning and evening
Matches both trials; morning use pairs with sunscreen given the ultraviolet-driven mechanism.
Finished-product reality
Percentage rarely disclosed
Serums and moisturizers rarely state the percentage, so the delivered dose may fall well below 1%.
Time to effect
Facial wrinkles
Week 8
Wrinkle grading separated from the inactive gel at week 8 and held at week 12.
Skin hydration
Week 8
Visually graded hydration improved over the inactive gel at weeks 8 and 12.
Facial redness
Week 4
Redness changes in the rosacea pilot appeared by week 4; nothing meaningful should be expected before then.

Benefits

Contraindications
  • Prior allergic contact dermatitis to this ingredient, another isoprenylcysteine, or the finished product
  • Broken, eroded, or actively infected skin (impetigo, active herpes simplex, scratched-open skin) until re-epithelialized
  • Pregnancy and breastfeeding
  • Moderate-to-severe papulopustular rosacea (Investigator Global Assessment grade 3 or 4) as a substitute for prescription therapy
  • Children under 12 years
    •
Key Interactions
  • Topical retinoids (tretinoin, adapalene, tazarotene, retinol)
  • Benzoyl peroxide
  • Exfoliating acids (glycolic, lactic, mandelic, salicylic)
  • Topical corticosteroids and calcineurin inhibitors (tacrolimus, pimecrolimus)
  • Prescription rosacea topicals (metronidazole, ivermectin, azelaic acid, brimonidine)
  • Other isoprenylcysteine actives (tetramethylhexadecenyl succinoyl cysteine, SIG-1273 products)
  • Vitamin C serums (L-ascorbic acid at pH below 3.5)
  • Procedures (fractional laser, microneedling, chemical peels)
    •

Risk & Side Effects

  • Low: Application-site irritation, stinging, or redness
    •
  • Speculative: Delayed allergic contact sensitization; chronic interference with prenylation-dependent signaling; masking of undiagnosed inflammatory skin disease

Monitoring

Marker Target Why
Crow's-feet wrinkle grade (photograph-graded 0–9) No established target; 1 point or more from own baseline by week 12 Primary endpoint of the controlled trial
Facial erythema index (spectrophotometer or photograph) No established target; 1–2 grades from own baseline Endpoint most tied to the anti-inflammatory mechanism
Stratum corneum hydration (corneometry) Above 50 arbitrary units on the cheek Objective substitute for the trial's visually graded hydration endpoint
Transepidermal water loss Below 10–15 g/m²/h on the face Barrier integrity; a rise signals irritation before it is visible
Investigator Global Assessment (0–4 clinician severity score) 0–1 (clear or almost clear) Endpoint used in the rosacea pilot
Skin surface pH 4.5–5.5 Acid mantle status; governs tolerance to layered actives

Cadence: Weeks 1 and 4 for tolerance, weeks 8 and 12 for appearance, then every 3–6 months while use continues

Qualitative Assessment

  • Stinging, burning, or tightness in the first 10 minutes after application
  • Frequency and duration of visible flushing episodes each week
  • How evenly makeup or sunscreen sits over the treated area
  • Morning skin comfort and the urge to apply a heavier moisturizer
  • Self-rated radiance and evenness in consistent lighting
Not medical advice. Educational distillation of a single evidence review. Confirm any decision with a qualified clinician, especially in the presence of prescription drugs or chronic conditions.